NVIDIA launched the UK’s most powerful supercomputer, enabling top scientists and healthcare experts to use the powerful combination of AI and simulation to speed the digital biology revolution and bolster the country’s world-leading life sciences industry.
Cambridge-1 Inauguration: Supercharging Healthcare and Life Sciences Research
Having trouble viewing this video? Watch it here.
Solving the Most Pressing Medical Challenges with AI
Cambridge-1 is accelerating health research that spans across medical imaging, genomics, and drug discovery. With its founding partners — AstraZeneca, GSK, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore— and other UK organizations, Cambridge-1 is dedicated to advancing UK health research through digital biology, unlocking a deeper understanding of disease and breakthroughs in medicine.
AstraZeneca - Founding Partner
Accelerating Drug Discovery with Machine Learning and AI
AstraZeneca is powering modern machine learning (ML) and AI to accelerate drug discovery with Cambridge-1, training models to learn the grammar of chemistry, and processing whole slide digital pathology images.
GSK - Founding Partner
Harnessing the Explosion of Medical Data for Transformative Treatments
AI is critical for unlocking the value of human genetics. With the computational resources of Cambridge-1, GSK is using advanced ML to harness genetic evidence in large databases and develop transformative medicine.
King's College London - Founding Partner
Generating Synthetic Brains to Combat Neurological Diseases
King’s College London is building deep learning models that can synthesize artificial 3D MRI images of human brains. Cambridge-1 enables accelerated generation of this synthetic data so researchers can understand how different factors affect the brain, anatomy, and pathology.
NHS - Founding Partner
Creating Faster Insights from Patient Data to Guide Treatments
Processing, handling, and reacting to large amounts of patient data from disparate systems is a key challenge for Guy’s and St Thomas’ NHS Foundation Trust. The NHS uses AI technologies that require supercomputing power to analyze and clean the data.
Oxford Nanopore - Founding Partner
Driving Discoveries with Accelerated Genomics Research
Oxford Nanopore is further accelerating its research with Cambridge-1, enabling its algorithms team to achieve same day results that accelerate research with more powerful and impactful genomics applications.
Peptone
Scaling AI-Driven Protein Engineering
Peptone aims to change the way protein drugs are engineered using unsupervised learning and reinforcement learning techniques. It plans to use Cambridge-1 to design antibodies that could help treat several inflammatory disorders.
Alchemab, InstaDeep, Relation Therapeutics
Powering Digital Biology Breakthroughs
Select NVIDIA Inception members are advancing drug discovery and research on Cambridge-1, researching antibody response, creating AI-powered decision-making systems for vaccine development, and mapping the causes of disease with recommender systems.
Photo Gallery
Powering the World’s Fastest Supercomputers
Cambridge-1 brings together decades of NVIDIA work in accelerated computing, AI, and life sciences into a single system: an NVIDIA DGX SuperPOD™ supercomputing cluster. Cambridge-1, powered by 100% renewable energy, now ranks among the world’s 50 fastest supercomputers.
Unbeatable AI Performance at Scale
NVIDIA DGX SuperPOD delivers a turnkey AI data center solution that allows researchers to focus on insights instead of infrastructure. A full-stack data center platform with best-of-breed computing, network fabric, storage, and software tools, along with a white-glove implementation service, ensures results in weeks instead of months. Learn more about the technology powering Cambridge-1.
Sign up for the latest NVIDIA healthcare news, including updates on Cambridge-1.